Greenwich Biosciences
Global biopharmaceutical company focused on developing and commercializing therapies in neuroscience, oncology and rare diseases. Operates R&D programs from preclinical through late-stage clinical development, runs global clinical trial programs, maintains manufacturing sites for clinical and commercial production, and provides pharmacovigilance and medical information services worldwide.
Industries
Nr. of Employees
large (251-1000)
Greenwich Biosciences
Products
Cannabidiol oral solution (Epidiolex/Epidyolex)
Plant-derived cannabidiol oral solution indicated for certain treatment-resistant seizure disorders; international regulatory approvals and country-specific prescribing information available.
Sodium oxybate formulations
Oral oxybate products indicated for narcolepsy-related conditions with region-specific prescribing information.
Liposomal daunorubicin + cytarabine (Vyxeos)
Liposomal combination chemotherapy formulation used in certain acute leukemias; developed and commercialized with global labeling and downloadable prescribing information for multiple jurisdictions.
Lurbinectedin
Small-molecule oncology agent evaluated and approved for small cell lung cancer in some markets and studied in combination regimens.
Investigational HER2-targeted bispecific antibody
Bispecific antibody program targeting HER2-expressing solid tumors undergoing multiple Phase 1–3 clinical studies across tumor types.
Investigational mitochondrial protease activator / DRD2 inhibitor (Modeyso/ONC201)
Investigational small molecule under Phase 3 evaluation for a molecularly defined diffuse glioma population; program focuses on mitochondrial protease activation and related mechanisms.
Cannabidiol oral solution (Epidiolex/Epidyolex)
Plant-derived cannabidiol oral solution indicated for certain treatment-resistant seizure disorders; international regulatory approvals and country-specific prescribing information available.
Sodium oxybate formulations
Oral oxybate products indicated for narcolepsy-related conditions with region-specific prescribing information.
Liposomal daunorubicin + cytarabine (Vyxeos)
Liposomal combination chemotherapy formulation used in certain acute leukemias; developed and commercialized with global labeling and downloadable prescribing information for multiple jurisdictions.
Lurbinectedin
Small-molecule oncology agent evaluated and approved for small cell lung cancer in some markets and studied in combination regimens.
Investigational HER2-targeted bispecific antibody
Bispecific antibody program targeting HER2-expressing solid tumors undergoing multiple Phase 1–3 clinical studies across tumor types.
Investigational mitochondrial protease activator / DRD2 inhibitor (Modeyso/ONC201)
Investigational small molecule under Phase 3 evaluation for a molecularly defined diffuse glioma population; program focuses on mitochondrial protease activation and related mechanisms.
Services
Clinical development programs
Design and execution of multi-phase clinical trials across oncology and neuroscience; clinical trial data sharing and plain-language summaries.
Expanded/Early access programs
Individual and multiple-patient early access pathways for investigational medicines in line with local regulations.
Medical information and pharmacovigilance services
Region-specific medical information support and global adverse event reporting infrastructure.
Partnering and alliance management
Licensing, collaborations and strategic acquisitions with a structured alliance management operating model.
Clinical development programs
Design and execution of multi-phase clinical trials across oncology and neuroscience; clinical trial data sharing and plain-language summaries.
Expanded/Early access programs
Individual and multiple-patient early access pathways for investigational medicines in line with local regulations.
Medical information and pharmacovigilance services
Region-specific medical information support and global adverse event reporting infrastructure.
Partnering and alliance management
Licensing, collaborations and strategic acquisitions with a structured alliance management operating model.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Neuroscience drug development
- Rare disease therapeutics
Key Technologies
- Bispecific antibody therapeutics
- Liposomal drug delivery
- Small-molecule kinase inhibitors
- Mitochondrial protease activator modalities